Brian Orelli

Cutting-edge technology meets traditional healthcare.

By catering to the needs of medical professionals, Doximity could deliver in a big way.

Positive clinical results should be a good thing, right?

Pfizer’s foreseeable future looks strong.

Trial design may matter more than you think.

What happens after a trial’s results are negative -- or positive?

Author Dr. Frank David breaks down what investors should look for when it comes to trial design.

Do some drug trial participants see improvements just because they’re told they might?

Is it time to buy a basket of biotech stocks?

Novavax’s milestone means investors can now exhale.

How will the cost of a settlement affect Gilead’s profits over the foreseeable future?

These underappreciated opportunities in healthcare are worth a closer look.

The biotech has an interesting pipeline, but it’s all early stage products.

Whether Fulgent is a value or a value trap depends on the short-term prospects for COVID-19 and the long-term prospects for its core sequencing business.

The biotech was priced for perfection; its data wasn’t.

Robert Califf got the nod, but current acting commissioner Janet Woodcock would have made a fine choice too.

The Swiss pharma needs to get its drug approved first.

Investors have bigger things to worry about.

The results were great news, but widely expected.

R&D spending is hurting earnings, but long-term investors shouldn’t be worried.